AP3402A - Splitting GP41 - Google Patents

Splitting GP41

Info

Publication number
AP3402A
AP3402A AP2011005853A AP2011005853A AP3402A AP 3402 A AP3402 A AP 3402A AP 2011005853 A AP2011005853 A AP 2011005853A AP 2011005853 A AP2011005853 A AP 2011005853A AP 3402 A AP3402 A AP 3402A
Authority
AP
ARIPO
Prior art keywords
splitting
Prior art date
Application number
AP2011005853A
Other languages
English (en)
Other versions
AP2011005853A0 (en
Inventor
Morgane Bomsel
Sylvain Fleury
Original Assignee
Mymetics Corp
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mymetics Corp, Inst Nat Sante Rech Med filed Critical Mymetics Corp
Publication of AP2011005853A0 publication Critical patent/AP2011005853A0/xx
Application granted granted Critical
Publication of AP3402A publication Critical patent/AP3402A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2011005853A 2009-02-06 2010-02-08 Splitting GP41 AP3402A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20221909P 2009-02-06 2009-02-06
US27266109P 2009-10-16 2009-10-16
PCT/EP2010/051524 WO2010089402A1 (fr) 2009-02-06 2010-02-08 Division de gp41

Publications (2)

Publication Number Publication Date
AP2011005853A0 AP2011005853A0 (en) 2011-08-31
AP3402A true AP3402A (en) 2015-08-31

Family

ID=42102985

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005853A AP3402A (en) 2009-02-06 2010-02-08 Splitting GP41

Country Status (12)

Country Link
US (1) US8652459B2 (fr)
EP (1) EP2393509A1 (fr)
KR (1) KR20110126636A (fr)
CN (1) CN102365095B (fr)
AP (1) AP3402A (fr)
AU (1) AU2010210073B2 (fr)
BR (1) BRPI1008721A2 (fr)
CA (1) CA2750067C (fr)
EA (1) EA025275B1 (fr)
MX (1) MX2011007745A (fr)
WO (1) WO2010089402A1 (fr)
ZA (1) ZA201105357B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511295A1 (fr) * 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions pour la prévention et/ou le traitement d'une infection par un virus VIH-1
RU2624046C2 (ru) 2011-11-07 2017-06-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Gp41-нейтрализующие антитела и их применение
CA3003878A1 (fr) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants diriges contre la proteine gp41 du vih-1 et leur utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010033A1 (fr) * 2003-07-30 2005-02-03 Mymetics Corporation Nouvelle forme trimere soluble et stabilisee de polypeptides gp41
WO2006117586A1 (fr) * 2005-05-02 2006-11-09 Mymetics Corporation Anticorps ou fragment de celui-ci, possedant une activite neutralisante contre le vih mais pas contre il2
WO2007099387A1 (fr) * 2006-03-03 2007-09-07 Mymetics Corporation Vésicules de type virosome comprenant des antigènes dérivés de gp41

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229703T2 (de) 1991-05-08 2000-04-27 Schweiz Serum & Impfinst Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe
EP0725825B1 (fr) * 1993-09-11 2001-02-21 Polymun Scientific Immunbiologische Forschung GmbH Peptides qui produisent des anticorps neutralisants contre des souches de vih-1 genetiquement divergentes
CN1195702A (zh) * 1997-04-08 1998-10-14 军事医学科学院基础医学研究所 Hiv－1多表位重组膜抗原及其表达
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
BR0303362A (pt) * 2002-03-06 2005-07-19 Univ Arizona State Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
AU2003288119B2 (en) 2002-11-21 2009-08-20 Pevion Biotech Ltd. High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them
EP1447080A1 (fr) 2003-02-13 2004-08-18 Bestewil Holding B.V. Procéde de production de particules de type virosome
US7198791B2 (en) 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010033A1 (fr) * 2003-07-30 2005-02-03 Mymetics Corporation Nouvelle forme trimere soluble et stabilisee de polypeptides gp41
WO2006117586A1 (fr) * 2005-05-02 2006-11-09 Mymetics Corporation Anticorps ou fragment de celui-ci, possedant une activite neutralisante contre le vih mais pas contre il2
WO2007099387A1 (fr) * 2006-03-03 2007-09-07 Mymetics Corporation Vésicules de type virosome comprenant des antigènes dérivés de gp41
WO2007099446A2 (fr) * 2006-03-03 2007-09-07 Mymetics Corporation Vesicules de type virosome comprenant des antigenes derives de gp41

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATOBA N ET AL: "Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate", VACCINE, ELSEVIER LTD, GB LNKD- DOI:10.1016/J.VACCINE.2006.03.045, vol. 24, no. 23, 5 June 2006 (2006-06-05), pages 5047 - 5055, XP025151330 *
MATOBA NOBUYUKI ET AL: "Transcytosis-blocking Abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes", CURRENT HIV RESEARCH, vol. 6, no. 3, May 2008 (2008-05-01), pages 218 - 229, XP009132624 *

Also Published As

Publication number Publication date
WO2010089402A1 (fr) 2010-08-12
KR20110126636A (ko) 2011-11-23
EA201190097A1 (ru) 2012-02-28
CN102365095A (zh) 2012-02-29
AU2010210073A1 (en) 2011-07-21
CA2750067C (fr) 2018-08-21
AU2010210073B2 (en) 2016-06-09
EP2393509A1 (fr) 2011-12-14
WO2010089402A9 (fr) 2010-11-04
US20110311614A1 (en) 2011-12-22
US8652459B2 (en) 2014-02-18
BRPI1008721A2 (pt) 2016-03-08
ZA201105357B (en) 2012-03-28
CN102365095B (zh) 2015-11-25
MX2011007745A (es) 2011-12-08
CA2750067A1 (fr) 2010-08-12
EA025275B1 (ru) 2016-12-30
AP2011005853A0 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
ZA201204371B (en) Biofuels via hydrogenolysis-condensation
GB0904558D0 (en) Membranes
GB0909645D0 (en) Methods
GB0907350D0 (en) Methods
EP2418013A4 (fr) Membrane mosaïque de charge
GB0901001D0 (en) Methods
GB0912685D0 (en) Methods
PL2272638T3 (pl) Nóż
ZA201200006B (en) Surfoboard
ZA201105357B (en) Splitting gp41
GB0921373D0 (en) Vice-angle
GB0912159D0 (en) Methods
TWM372154U (en) Instant tree
GB0900924D0 (en) Instant kofta
AP3595A (en) Novel gp41 antigens
PL118669U1 (pl) Nóż styczno-obrotowy
PL2258482T3 (pl) Kuter
GB0910666D0 (en) Rowing-boat span-guages
TWI365604B (en) Delay circiuit
GB0919461D0 (en) Structural members
GB0900167D0 (en) B b
TWM372245U (en) Pliers structure
GB0903349D0 (en) Concept four
TWM387759U (en) Cutter
GB0907959D0 (en) Easy line-eyeliner